







## EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	84	vidya.inv. and lohray.inv.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/05/14 15:17
L2	236	nagao.inv. and Yoshihiro.inv.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/05/14 16:25
L3	497	(544/283).CCLS.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/05/14 16:25
L5	198	(514/266.1).CCLS.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/05/14 16:27
L6	88	braj.inv. and lohray.inv.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/05/14 16:28
L7	9	braj.inv. and lohray.inv. and quinazoline	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/05/14 16:28
L8	10	rao.inv. and paraselli.inv. and quinazoline	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/05/14 16:29
L9	10	rajagopalan.inv. and ramanujam.inv. and quinazoline	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/05/14 16:29
L10	9	ranjan.inv. and chakrabarti.inv. and quinazoline	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/05/14 16:29

## EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	84	vidya.inv. and lohray.inv.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/05/14 15:17
L2	236	nagao.inv. and Yoshihiro.inv.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/05/14 16:25
L3	497	(544/283).CCLS.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/05/14 16:25
L5	198	(514/266.1).CCLS.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/05/14 16:27
L6	88	braj.inv. and lohray.inv.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/05/14 16:28
L7	9	braj.inv. and lohray.inv. and quinazoline	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/05/14 16:28
L8	10	rao.inv. and paraselli.inv. and quinazoline	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/05/14 16:29
L9	10	rajagopalan.inv. and ramanujam. inv. and quinazoline	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/05/14 16:29
L10	9	ranjan.inv. and chakrabarti.inv. and quinazoline	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/05/14 16:29



**chain nodes :**  
 11 24 25 26 27 28 30 31 32 33 34 35 40  
**ring nodes :**  
 1 2 3 4 5 6 7 8 9 10 14 15 16 17 18 19 20 21 22 23  
**chain bonds :**  
 7-11 20-24 25-26 25-40 26-27 27-28 28-30 30-31 31-32 31-35 32-33 32-34  
**ring bonds :**  
 1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 14-15 14-19 15-16 16-17  
 17-18 18-19 18-20 19-23 20-21 21-22 22-23  
**exact/norm bonds :**  
 5-7 6-10 7-8 7-11 8-9 9-10 18-20 19-23 20-21 20-24 21-22 22-23 25-40 27-28  
 28-30 31-35 32-33 32-34  
**exact bonds :**  
 25-26 26-27 30-31 31-32  
**normalized bonds :**  
 1-2 1-6 2-3 3-4 4-5 5-6 14-15 14-19 15-16 16-17 17-18 18-19

**isolated ring systems :**  
 containing 1 : 14 :

G1:O,S

G2:O,N

G3:[\*1], [\*2]

**Match level :**

- 1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:CLASS
- 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom 22:Atom 23:Atom
- 24:CLASS 25:CLASS 26:CLASS 27:CLASS 28:Atom 30:CLASS 31:CLASS 32:CLASS 33:CLASS
- 34:CLASS 35:CLASS 40:CLASS

**Generic attributes :**

28:  
Saturation : Unsaturated  
Number of Carbon Atoms : less than 7  
Type of Ring System : Monocyclic

Element Count :  
Node 28: Limited  
O,OO  
S,S0  
N,N0

## Connecting via Winsock to STN

Welcome to STN International! Enter x:

x

Welcome to STN International! Enter x:

LOGINID: ssspta1611bxv

**PASSWORD:**

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* \* \* \* \* \* \* \* \* \* \* Welcome to STN International \* \* \* \* \* \* \* \* \* \* \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 JAN 17 Pre-1988 INPI data added to MARPAT  
NEWS 4 FEB 21 STN AnaVist, Version 1.1, lets you share your STN AnaVist visualization results  
NEWS 5 FEB 22 The IPC thesaurus added to additional patent databases on STN  
NEWS 6 FEB 22 Updates in EPFULL; IPC 8 enhancements added  
NEWS 7 FEB 27 New STN AnaVist pricing effective March 1, 2006  
NEWS 8 MAR 03 Updates in PATDPA; addition of IPC 8 data without attributes  
NEWS 9 MAR 08 X.25 communication option no longer available after June 2006  
NEWS 10 MAR 22 EMBASE is now updated on a daily basis  
NEWS 11 APR 03 New IPC 8 fields and IPC thesaurus added to PATDPAFULL  
NEWS 12 APR 03 Bibliographic data updates resume; new IPC 8 fields and IPC thesaurus added in PCTFULL  
NEWS 13 APR 04 STN AnaVist \$500 visualization usage credit offered  
NEWS 14 APR 12 LINSPEC, learning database for INSPEC, reloaded and enhanced  
NEWS 15 APR 12 Improved structure highlighting in FQHIT and QHIT display in MARPAT  
NEWS 16 APR 12 Derwent World Patents Index to be reloaded and enhanced during second quarter; strategies may be affected  
NEWS 17 MAY 10 CA/CAplus enhanced with 1900-1906 U.S. patent records  
NEWS 18 MAY 11 KOREAPAT updates resume  
  
NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a,  
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.  
V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT  
<http://download.cas.org/express/v8.0-Discover/>  
  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

**COMPLETE THE STN SURVEY - APRIL 27 THROUGH MAY 31**

Dear valued STN customer,

In an effort to enhance your experience with STN, we would like to better understand what you find useful. Please take approximately 5 minutes to complete a web survey.

If you provide us with your name, login ID, and e-mail address, you will be entered in a drawing to win a free iPod(R). Your responses will be kept confidential and will help us make future improvements to STN.

Take survey: <http://www.zoomerang.com/survey.zqi?p=WEB2259HNKWTUW>

**Thank you in advance for your participation.**

FILE 'HOME' ENTERED AT 15:53:40 ON 14 MAY 2006

FILE 'REGISTRY' ENTERED AT 15:53:49 ON 14 MAY 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 12 MAY 2006 HIGHEST RN 884047-29-4  
DICTIONARY FILE UPDATES: 12 MAY 2006 HIGHEST RN 884047-29-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

```
*****
* The CA roles and document type information have been removed from
* the IDE default display format and the ED field has been added,
* effective March 20, 2005. A new display format, IDERL, is now
* available and contains the CA role and document type information.
*****
*****
```

Structure search iteration limits have been increased. See HELP SLIMITS for details.


REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

09/179,002

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\09179002RAYBAL.str



chain nodes :  
11 24 25 26 27 28 30 31 32 33 34 35 40  
ring nodes :  
1 2 3 4 5 6 7 8 9 10 14 15 16 17 18 19 20 21 22 23  
chain bonds :  
7-11 20-24 25-26 25-40 26-27 27-28 28-30 30-31 31-32 31-35 32-33 32-34  
ring bonds :  
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 14-15 14-19 15-16 16-17  
17-18 18-19 18-20 19-23 20-21 21-22 22-23  
exact/norm bonds :  
5-7 6-10 7-8 7-11 8-9 9-10 18-20 19-23 20-21 20-24 21-22 22-23 25-40  
27-28 28-30 31-35 32-33 32-34  
exact bonds :  
25-26 26-27 30-31 31-32  
normalized bonds :  
1-2 1-6 2-3 3-4 4-5 5-6 14-15 14-19 15-16 16-17 17-18 18-19  
isolated ring systems :  
containing 1 : 14 :

G1:O,S

G2:O,N

G3:[\*1],[\*2]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
11:CLASS 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom  
22:Atom 23:Atom 24:CLASS 25:CLASS 26:CLASS 27:CLASS 28:Atom 30:CLASS  
31:CLASS 32:CLASS 33:CLASS 34:CLASS 35:CLASS 40:CLASS

09/179,002

Generic attributes :  
28:  
Saturation : Unsaturated  
Number of Carbon Atoms : less than 7  
Type of Ring System : Monocyclic

Element Count :  
Node 28: Limited  
O,OO  
S,S0  
N,N0


L1 STRUCTURE UPLOADED

=> d 11  
L1 HAS NO ANSWERS  
L1 STR  
  
\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*  
Structure attributes must be viewed using STN Express query preparation.

=> s 11 sss sam  
SAMPLE SEARCH INITIATED 15:54:15 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 175 TO ITERATE  
  
100.0% PROCESSED 175 ITERATIONS 5 ANSWERS  
SEARCH TIME: 00.00.01  
  
FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 2707 TO 4293  
PROJECTED ANSWERS: 5 TO 234

L2 5 SEA SSS SAM L1

=> d scan  
  
L2 5 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Benzenepropanoic acid, 4-[(3-(3-chloro-4-fluorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl)methoxy]- $\alpha$ -ethoxy-, ethyl ester (9CI)  
MF C28 H26 Cl F N2 O5



09/179,002


\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):4


L2 5 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, ( $\alpha$ S)-, compd. with hydrazinecarboximidamide (1:1), monoformate (9CI)  
MF C23 H26 N2 O5 . C H6 N4 . C H2 O2

CM 1

Absolute stereochemistry. Rotation (-).




CM 2



CM 3



L2 5 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Benzenepropanoic acid, 4-[(3-(3-chloro-4-fluorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl)methoxy]- $\alpha$ -ethoxy- (9CI)  
MF C26 H22 Cl F N2 O5




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

09/179,002


L2 5 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN D-Glucitol, 1-deoxy-1-(octylamino)-,  $\alpha$ -ethoxy-4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]benzenepropanoate (salt) (9CI)  
MF C23 H26 N2 O5 . C14 H31 N O5

CM 1



CM 2


Absolute stereochemistry. Rotation (-).




L2 5 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, ( $\alpha$ S)-, compd. with  $\beta$ -aminobenzeneethanol (1:1) (9CI)  
MF C23 H26 N2 O5 . C8 H11 N O

CM 1

Absolute stereochemistry. Rotation (-).



CM 2



09/179,002

ALL ANSWERS HAVE BEEN SCANNED

=> s 11 sss ful

FULL SEARCH INITIATED 15:54:31 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 3434 TO ITERATE

100.0% PROCESSED 3434 ITERATIONS  
SEARCH TIME: 00.00.01

104 ANSWERS

L3 104 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

ENTRY

TOTAL

FULL ESTIMATED COST

SESSION

SESSION

166.94 167.15

FILE 'CAPLUS' ENTERED AT 15:54:39 ON 14 MAY 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 14 May 2006 VOL 144 ISS 21  
FILE LAST UPDATED: 12 May 2006 (20060512/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 13


L4 3 L3

=> d 14 1-3 bib hitstr

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2002:615616 CAPLUS  
DN 137:169540  
TI Preparation of pharmaceutically acceptable salts of nitrogen-containing heterocyclic compounds as remedies for type II diabetes and disorders related to Syndrome X and endothelial cell activation  
IN Gaddam, Om Reddy; Batchu, Chandrasekhar; Potlapally, Rajender Kumar; Mamillapalli, Ramabhadra Sarma; Paraselli, Bheema Rao; Mamidi, Naga Venkata Srinivasa Rao  
PA Reddy's Research Foundation, India  
SO PCT Int. Appl., 129 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002062798 WO 2002062798	A2 A3	20020815 20021205	WO 2002-IB312	20020205
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2002169175	A1	20021114	US 2002-67094	20020204
	CA 2436738	AA	20020815	CA 2002-2436738	20020205
	EP 1363913	A2	20031126	EP 2002-711124	20020205
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004520393	T2	20040708	JP 2002-563151	20020205
PRAI	US 2001-266595P	P	20010205		
	IN 2001-MA813	A	20011004		
	WO 2002-IB312	W	20020205		
OS	CASREACT 137:169540; MARPAT 137:169540				
IT	<b>446290-93-3P 446290-94-4P 446290-95-5P</b> <b>446290-96-6P 446290-97-7P 446290-98-8P</b> <b>446290-99-9P 446291-00-5P 446291-01-6P</b> <b>446291-03-8P 446291-10-7P 446291-52-7P</b> <b>446291-53-8P 446291-54-9P 446291-55-0P</b> <b>446291-56-1P 446291-57-2P 446291-58-3P</b> <b>446291-59-4P 446291-60-7P 446291-61-8P</b> <b>446291-62-9P 446291-63-0P 446291-64-1P</b> <b>446291-65-2P 446291-66-3P 446291-67-4P</b> <b>446291-68-5P 446291-69-6P 446291-70-9P</b> <b>446291-71-0P 446291-72-1P 446291-73-2P</b> <b>446291-74-3P 446291-75-4P 446291-76-5P</b> <b>446292-98-4P</b>				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of pharmaceutically acceptable salts of nitrogen-containing heterocyclic compds. as remedies for type II diabetes and disorders related to Syndrome X and endothelial cell activation)				
RN	446290-93-3 CAPLUS				
CN	Benzene propanoic acid, $\alpha$ -ethoxy-4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, ( $\alpha$ S)-, compd. with $\beta$ -aminobenzeneethanol (1:1) (9CI) (CA INDEX NAME)				
	CM 1				
	CRN 220746-54-3				
	CMF C23 H26 N2 O5				


Absolute stereochemistry. Rotation (-).



CM 2

CRN 7568-92-5

CMF C8 H11 N O




RN 446290-94-4 CAPLUS

CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, ( $\alpha$ S)-, compd. with ( $\alpha$ R)- $\alpha$ -methylbenzenemethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 220746-54-3


CMF C23 H26 N2 O5

**Absolute stereochemistry.** Rotation (-).

CM 2

CRN 3886-69-9

CMF C8 H11 N

**Absolute stereochemistry.** Rotation (+).

RN 446290-95-5 CAPLUS


CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, ( $\alpha$ S)-, compd. with N-cyclohexylcyclohexanamine (1:1) (9CI) (CA INDEX NAME)

09/179,002

CM 1


CRN 220746-54-3  
CMF C23 H26 N2 O5

Absolute stereochemistry. Rotation (-).



CM 2

CRN 101-83-7  
CMF C12 H23 N




RN 446290-96-6 CAPLUS

CN L-Lysine, mono[( $\alpha$ S)- $\alpha$ -ethoxy-4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 220746-54-3  
CMF C23 H26 N2 O5


Absolute stereochemistry. Rotation (-).



CM 2

CRN 56-87-1  
CMF C6 H14 N2 O2

Absolute stereochemistry.



RN 446290-97-7 CAPLUS


CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, ( $\alpha S$ )-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 220746-54-3

CMF C23 H26 N2 O5


Absolute stereochemistry. Rotation (-).



CM 2

CRN 77-86-1

CMF C4 H11 N O3



RN 446290-98-8 CAPLUS

CN D-Glucitol, 1-deoxy-1-(octylamino)-, ( $\alpha S$ )- $\alpha$ -ethoxy-4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]benzenepropanoate (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 220746-54-3

CMF C23 H26 N2 O5

Absolute stereochemistry. Rotation (-).


09/179,002



CM 2

CRN 23323-37-7  
CMF C14 H31 N O5

Absolute stereochemistry. Rotation (-).




RN 446290-99-9 CAPLUS  
CN D-Glucitol, 1-deoxy-1-(methylamino)-, ( $\alpha$ S)- $\alpha$ -ethoxy-4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]benzenepropanoate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 220746-54-3  
CMF C23 H26 N2 O5


Absolute stereochemistry. Rotation (-).



CM 2

CRN 6284-40-8  
CMF C7 H17 N O5

Absolute stereochemistry.



RN 446291-00-5 CAPLUS


CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, ( $\alpha$ S)-, compd. with hydrazinecarboximidamide (1:1), monoformate (9CI) (CA INDEX NAME)

CM 1

CRN 220746-54-3

CMF C23 H26 N2 O5


Absolute stereochemistry. Rotation (-).



CM 2

CRN 79-17-4


CMF C H6 N4



CM 3

CRN 64-18-6


CMF C H2 O2



RN 446291-01-6 CAPLUS

CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, lithium salt, ( $\alpha$ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● Li

RN 446291-03-8 CAPLUS


CN L-Arginine, mono[(αS)-α-ethoxy-4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 220746-54-3

CMF C23 H26 N2 O5

Absolute stereochemistry. Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.



RN 446291-10-7 CAPLUS

CN Benzenepropanoic acid, α-ethoxy-4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, (αS)-, compd. with N,N-dimethylimidodicarbonimidic diamide (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 220746-54-3

CMF C23 H26 N2 O5


Absolute stereochemistry. Rotation (-).

09/179,002



CM 2

CRN 657-24-9  
CMF C4 H11 N5




RN 446291-52-7 CAPLUS

CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, compd. with  $\beta$ -aminobenzeneethanol (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 220746-50-9  
CMF C23 H26 N2 O5



CM 2

CRN 7568-92-5  
CMF C8 H11 N O



RN 446291-53-8 CAPLUS


CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, ( $\alpha$ R)-, compd. with  $\beta$ -aminobenzeneethanol (1:1) (9CI) (CA INDEX NAME)

CM 1

09/179,002


CRN 220746-53-2  
CMF C23 H26 N2 O5

Absolute stereochemistry. Rotation (+).



CM 2

CRN 7568-92-5  
CMF C8 H11 N O




RN 446291-54-9 CAPLUS

CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, compd. with  $\alpha$ -methylbenzenemethanamine (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 220746-50-9  
CMF C23 H26 N2 O5



CM 2

CRN 618-36-0  
CMF C8 H11 N



RN 446291-55-0 CAPLUS


09/179,002

CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, ( $\alpha R$ )-, compd. with  $\alpha$ -methylbenzenemethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 220746-53-2  
CMF C23 H26 N2 O5

Absolute stereochemistry. Rotation (+).



CM 2

CRN 618-36-0  
CMF C8 H11 N




RN 446291-56-1 CAPLUS

CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, ( $\alpha S$ )-, compd. with  $\alpha$ -methylbenzenemethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 220746-54-3  
CMF C23 H26 N2 O5

Absolute stereochemistry. Rotation (-).



CM 2

CRN 618-36-0  
CMF C8 H11 N




RN 446291-57-2 CAPLUS

CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, compd. with N-cyclohexylcyclohexanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 220746-50-9


CMF C23 H26 N2 O5



CM 2

CRN 101-83-7

CMF C12 H23 N



RN 446291-58-3 CAPLUS


CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, ( $\alpha$ R)-, compd. with N-cyclohexylcyclohexanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 220746-53-2

CMF C23 H26 N2 O5


Absolute stereochemistry. Rotation (+).



09/179,002

CM 2


CRN 101-83-7  
CMF C12 H23 N



RN 446291-59-4 CAPLUS  
CN L-Lysine, mono[ $\alpha$ -ethoxy-4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1


CRN 220746-50-9  
CMF C23 H26 N2 O5



CM 2

CRN 56-87-1  
CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 446291-60-7 CAPLUS  
CN L-Lysine, mono[( $\alpha$ R)- $\alpha$ -ethoxy-4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 220746-53-2  
CMF C23 H26 N2 O5

Absolute stereochemistry. Rotation (+).




CM 2

CRN 56-87-1

CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 446291-61-8 CAPLUS

CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 220746-50-9


CMF C23 H26 N2 O5



CM 2

CRN 77-86-1

CMF C4 H11 N O3



RN 446291-62-9 CAPLUS

CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(2-ethyl-4-oxo-3(4H)-


09/179,002

quinazolinyl)ethoxy]-, ( $\alpha$ R)-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 220746-53-2  
CMF C23 H26 N2 O5

Absolute stereochemistry. Rotation (+).



CM 2


CRN 77-86-1  
CMF C4 H11 N O3



RN 446291-63-0 CAPLUS  
CN D-Glucitol, 1-deoxy-1-(octylamino)-,  $\alpha$ -ethoxy-4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]benzenepropanoate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 220746-50-9  
CMF C23 H26 N2 O5




CM 2

CRN 23323-37-7  
CMF C14 H31 N O5

Absolute stereochemistry. Rotation (-).

09/179,002



RN 446291-64-1 CAPLUS


CN D-Glucitol, 1-deoxy-1-(octylamino)-, ( $\alpha$ R)- $\alpha$ -ethoxy-4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]benzenepropanoate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 220746-53-2

CMF C23 H26 N2 O5

Absolute stereochemistry. Rotation (+).




CM 2

CRN 23323-37-7

CMF C14 H31 N O5

Absolute stereochemistry. Rotation (-).




RN 446291-65-2 CAPLUS

CN D-Glucitol, 1-deoxy-1-(methylamino)-,  $\alpha$ -ethoxy-4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]benzenepropanoate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 220746-50-9


CMF C23 H26 N2 O5



CM 2

CRN 6284-40-8  
CMF C7 H17 N O5

Absolute stereochemistry.




RN 446291-66-3 CAPLUS

CN D-Glucitol, 1-deoxy-1-(methylamino)-, ( $\alpha$ R)- $\alpha$ -ethoxy-4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]benzenepropanoate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 220746-53-2  
CMF C23 H26 N2 O5

Absolute stereochemistry. Rotation (+).




CM 2

CRN 6284-40-8  
CMF C7 H17 N O5

Absolute stereochemistry.

09/179,002




RN 446291-67-4 CAPLUS

CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, compd. with hydrazinecarboximidamide (1:1), monoformate (9CI) (CA INDEX NAME)

CM 1

CRN 220746-50-9


CMF C23 H26 N2 O5



CM 2

CRN 79-17-4

CMF C H6 N4



CM 3

CRN 64-18-6

CMF C H2 O2



RN 446291-68-5 CAPLUS

CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, ( $\alpha$ R)-, compd. with hydrazinecarboximidamide (1:1), monoformate (9CI) (CA INDEX NAME)


CM 1

CRN 220746-53-2

CMF C23 H26 N2 O5


09/179,002

Absolute stereochemistry. Rotation (+).



CM 2

CRN 79-17-4  
CMF C H6 N4




CM 3

CRN 64-18-6  
CMF C H2 O2



RN 446291-69-6 CAPLUS

CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, lithium salt (9CI) (CA INDEX NAME)




● Li

RN 446291-70-9 CAPLUS

CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, lithium salt, ( $\alpha$ R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● Li


RN 446291-71-0 CAPLUS

CN L-Arginine, mono[ $\alpha$ -ethoxy-4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 220746-50-9

CMF C23 H26 N2 O5




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.



RN 446291-72-1 CAPLUS

CN L-Arginine, mono[( $\alpha$ R)- $\alpha$ -ethoxy-4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)


CM 1

CRN 220746-53-2

CMF C23 H26 N2 O5

Absolute stereochemistry. Rotation (+).

09/179,002




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.




RN 446291-73-2 CAPLUS

CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, compd. with N,N-dimethylimidodicarbonimidic diamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 220746-50-9


CMF C23 H26 N2 O5



CM 2

CRN 657-24-9

CMF C4 H11 N5



RN 446291-74-3 CAPLUS

CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, ( $\alpha$ R)-, compd. with N,N-


09/179, 002

dimethylimidodicarbonimidic diamide (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 220746-53-2  
CMF C23 H26 N2 O5

Absolute stereochemistry. Rotation (+).



CM 2

CRN 657-24-9  
CMF C4 H11 N5




RN 446291-75-4 CAPLUS

CN Benzene propanoic acid,  $\alpha$ -ethoxy-4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, compd. with 1H-imidazole (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 220746-50-9  
CMF C23 H26 N2 O5



CM 2

CRN 288-32-4  
CMF C3 H4 N2



RN 446291-76-5 CAPLUS


CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, ( $\alpha$ R)-, compd. with 1H-imidazole (1:1) (9CI)  
(CA INDEX NAME)

CM 1

CRN 220746-53-2

CMF C23 H26 N2 O5


Absolute stereochemistry. Rotation (+).



CM 2

CRN 288-32-4

CMF C3 H4 N2



RN 446292-98-4 CAPLUS


CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, ( $\alpha$ S)-, compd. with 1H-imidazole (1:1) (9CI)  
(CA INDEX NAME)

CM 1


CRN 220746-54-3

CMF C23 H26 N2 O5

Absolute stereochemistry. Rotation (-).



CM 2

CRN 288-32-4  
CMF C3 H4 N2


IT 220746-52-1 220746-54-3

RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of pharmaceutically acceptable salts of nitrogen-containing heterocyclic compds. as remedies for type II diabetes and disorders related to Syndrome X and endothelial cell activation)

RN 220746-52-1 CAPLUS

CN Benzenepropanamide,  $\alpha$ -ethoxy-4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-N-[(1S)-2-hydroxy-1-phenylethyl]-, ( $\alpha$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 220746-54-3 CAPLUS

CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, ( $\alpha$ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 446291-05-0 446291-07-2 446291-09-4


RL: RCT (Reactant); RACT (Reactant or reagent)  
(reactant; preparation of pharmaceutically acceptable salts of nitrogen-containing heterocyclic compds. as remedies for type II diabetes and disorders related to Syndrome X and endothelial cell activation)

RN 446291-05-0 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2-azido-4-oxo-3(4H)-quinazolinyl)ethoxy]- $\alpha$ -ethoxy-, ( $\alpha$ S)- (9CI) (CA INDEX NAME)

09/179,002


Absolute stereochemistry. Rotation (-).



RN 446291-07-2 CAPLUS

CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-[2-(4-morpholinyl)-4-oxo-3(4H)-quinazolinyl]ethoxy]-, ( $\alpha$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 446291-09-4 CAPLUS

CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-[4-oxo-2-(1-piperidinyl)-3(4H)-quinazolinyl]ethoxy]-, ( $\alpha$ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1999:209142 CAPLUS

DN 130:237584

TI  $\alpha$ -Substituted phenylpropionic acid derivatives for use as antidiabetics

IN Nagao, Yoshihiro; Konno, Fujiko; Kotake, Jiro; Ishii, Fumio; Honda, Haruyoshi; Sato, Susumu

PA SSP Co., Ltd., Japan

SO Eur. Pat. Appl., 52 pp.  
CODEN: EPXXDW


DT Patent

LA English

FAN.CNT 1

09/179,002

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 903343	A1	19990324	EP 1998-117153	19980910
	EP 903343	B1	20030528		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO ES 2200248	T3	20040301	ES 1998-117153	19980910
	JP 11158144	A2	19990615	JP 1998-258493	19980911
	TW 474922	B	20020201	TW 1998-87115261	19980914
	CA 2247772	AA	19990319	CA 1998-2247772	19980916
	CN 1215051	A	19990428	CN 1998-119631	19980918
PRAI	JP 1997-255025	A	19970919		
OS	MARPAT 130:237584				
IT	<b>221321-84-2P</b>				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of $\alpha$ -substituted phenylpropionic acid derivs. for use as antidiabetics)				
RN	221321-84-2 CAPLUS				
CN	Benzene propanamide, $\alpha$ -ethoxy-4-[2-(4-oxo-3(4H)-quinazolinyl)ethoxy]-(9CI) (CA INDEX NAME)				



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 1999:152363 CAPLUS  
 DN 130:196665  
 TI Preparation of  $\omega$ -[(oxoquinazolinylalkoxy)phenyl]alkanoates and analogs as PPAR $\alpha$  and PPAR $\gamma$  receptor agonists  
 IN Lohray, Vidya Hushan; Lohray, Braj Bhushan; Paraselli, Rao Bheema;  
 Ramanujam, Rajagopalan; Chakrabarti, Ranjan  
 PA Reddy's Research Foundation, India; Reddy-Cheminor, Inc.  
 SO PCT Int. Appl., 140 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9908501	A2	19990225	WO 1998-US22568	19981026
	WO 9908501	A3	19990415		
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,				

CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 9911205	A1 19990308	AU 1999-11205	19981026
EP 1073643	A2 20010207	EP 1998-953969	19981026
EP 1073643	B1 20041229		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO

AT 286032	E 20050115	AT 1998-953969	19981026
PRAI US 1998-82825P	P 19980423		
WO 1998-US22568	W 19981026		


OS MARPAT 130:196665

IT 220746-16-7P 220746-17-8P 220746-18-9P  
 220746-19-0P 220746-20-3P 220746-21-4P  
 220746-22-5P 220746-23-6P 220746-25-8P  
 220746-26-9P 220746-27-0P 220746-28-1P  
 220746-29-2P 220746-30-5P 220746-31-6P  
 220746-32-7P 220746-33-8P 220746-34-9P  
 220746-35-0P 220746-36-1P 220746-37-2P  
 220746-39-4P 220746-42-9P 220746-43-0P  
 220746-45-2P 220746-47-4P 220746-48-5P  
 220746-49-6P 220746-50-9P 220746-51-0P  
 220746-52-1P 220746-53-2P 220746-54-3P  
 220746-56-5P 220746-57-6P 220746-58-7P  
 220746-59-8P 220746-60-1P 220746-61-2P  
 220746-62-3P 220746-63-4P 220746-64-5P  
 220746-65-6P 220746-66-7P 220746-67-8P  
 220746-68-9P 220746-70-3P 220746-71-4P  
 220746-72-5P 220746-75-8P 220746-76-9P  
 220746-77-0P 220746-78-1P 220746-79-2P  
 220746-80-5P 220746-81-6P 220746-82-7P  
 220746-83-8P 220746-85-0P 220746-86-1P  
 220746-87-2P 220746-88-3P 220746-89-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of  $\omega$ -[(oxoquinazolinylalkoxy)phenyl]alkanoates and analogs as PPAR $\alpha$  and PPAR $\gamma$  receptor agonists)

RN 220746-16-7 CAPLUS


CN Benzene propanoic acid, 4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]- $\alpha$ -ethoxy-, ethyl ester (9CI) (CA INDEX NAME)



RN 220746-17-8 CAPLUS


CN Benzene propanoic acid, 4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]- $\alpha$ -ethoxy- (9CI) (CA INDEX NAME)

09/179,002



RN 220746-18-9 CAPLUS

CN Benzenepropanoic acid, 4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]-α-ethoxy-, sodium salt (9CI) (CA INDEX NAME)




● Na

RN 220746-19-0 CAPLUS

CN Benzenepropanamide, 4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]-α-ethoxy-N-[(1S)-2-hydroxy-1-phenylethyl]-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 220746-20-3 CAPLUS

CN Benzenepropanamide, 4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]-α-ethoxy-N-[(1S)-2-hydroxy-1-phenylethyl]-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 220746-21-4 CAPLUS

CN Benzene propanoic acid, 4-[ (3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]-α-ethoxy-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 220746-22-5 CAPLUS

CN Benzene propanoic acid, 4-[ (3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]-α-ethoxy-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 220746-23-6 CAPLUS

CN Benzene propanoic acid, 4-[ (3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]-α-ethoxy-, sodium salt, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



● Na


RN 220746-25-8 CAPLUS

CN Benzenepropanamide, 4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]- $\alpha$ -ethoxy-N-(2-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 220746-26-9 CAPLUS

CN Benzenepropanoic acid, 4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]- $\alpha$ -hydroxy-, ethyl ester (9CI) (CA INDEX NAME)




RN 220746-27-0 CAPLUS

CN Benzenepropanoic acid, 4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]- $\alpha$ -hydroxy- (9CI) (CA INDEX NAME)




RN 220746-28-1 CAPLUS

CN Benzenepropanoic acid, 4-[ (3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]-alpha-methoxy-, ethyl ester (9CI) (CA INDEX NAME)




RN 220746-29-2 CAPLUS

CN Benzenepropanoic acid, 4-[ (3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]-alpha-methoxy- (9CI) (CA INDEX NAME)



RN 220746-30-5 CAPLUS


CN Benzenepropanoic acid, 4-[ (3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]-alpha-propoxy-, ethyl ester (9CI) (CA INDEX NAME)



RN 220746-31-6 CAPLUS

09/179,002


CN Benzenepropanoic acid, 4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]- $\alpha$ -propoxy- (9CI) (CA INDEX NAME)



RN 220746-32-7 CAPLUS

CN Benzenepropanamide, 4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]-N-[(1S)-2-hydroxy-1-phenylethyl]- $\alpha$ -propoxy-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220746-33-8 CAPLUS


CN Benzenepropanamide, 4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]-N-[(1S)-2-hydroxy-1-phenylethyl]- $\alpha$ -propoxy-, ( $\alpha$ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220746-34-9 CAPLUS


CN Benzenepropanoic acid,  $\alpha$ -butoxy-4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 220746-35-0 CAPLUS

CN Benzenepropanoic acid,  $\alpha$ -butoxy-4-[ (3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]- (9CI) (CA INDEX NAME)

RN 220746-36-1 CAPLUS

CN Benzenepropanoic acid, 4-[ (3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]- $\alpha$ -(octyloxy)-, ethyl ester (9CI) (CA INDEX NAME)


RN 220746-37-2 CAPLUS

CN Benzenepropanoic acid, 4-[ (3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]- $\alpha$ -(octyloxy)- (9CI) (CA INDEX NAME)

09/179,002


RN 220746-39-4 CAPLUS

CN Benzenepropanoic acid, 4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]- $\alpha$ -(phenylmethoxy)-, ethyl ester (9CI) (CA INDEX NAME)




RN 220746-42-9 CAPLUS

CN Benzenepropanoic acid, 4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]- $\alpha$ -(phenylmethoxy)- (9CI) (CA INDEX NAME)




RN 220746-43-0 CAPLUS

CN Benzenepropanoic acid, 4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]- $\alpha$ -phenoxy-, ethyl ester (9CI) (CA INDEX NAME)




RN 220746-45-2 CAPLUS

CN Benzenepropanoic acid, 4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]- $\alpha$ -phenoxy- (9CI) (CA INDEX NAME)




RN 220746-47-4 CAPLUS

CN Benzenepropanoic acid, 4-[ (3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]-α-(2-methoxyethoxy)-, ethyl ester (9CI) (CA INDEX NAME)




RN 220746-48-5 CAPLUS

CN Benzenepropanoic acid, 4-[ (3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]-α-(2-methoxyethoxy)- (9CI) (CA INDEX NAME)



RN 220746-49-6 CAPLUS


CN Benzenepropanoic acid, α-ethoxy-4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 220746-50-9 CAPLUS

09/179,002


CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 220746-51-0 CAPLUS

CN Benzenepropanamide,  $\alpha$ -ethoxy-4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-N-[(1S)-2-hydroxy-1-phenylethyl]-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 220746-52-1 CAPLUS

CN Benzenepropanamide,  $\alpha$ -ethoxy-4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-N-[(1S)-2-hydroxy-1-phenylethyl]-, ( $\alpha$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 220746-53-2 CAPLUS

CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 220746-54-3 CAPLUS

CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, ( $\alpha$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 220746-56-5 CAPLUS

CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, ethyl ester, ( $\alpha$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 220746-57-6 CAPLUS

CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, ethyl ester, ( $\alpha$ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 220746-58-7 CAPLUS

CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(2-methyl-4-oxo-3(4H)-


09/179,002

quinazolinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 220746-59-8 CAPLUS


CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(2-methyl-4-oxo-3(4H)-quinazolinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 220746-60-1 CAPLUS

CN Benzenepropanamide,  $\alpha$ -ethoxy-N-[(1S)-2-hydroxy-1-phenylethyl]-4-[2-(2-methyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220746-61-2 CAPLUS

CN Benzenepropanamide,  $\alpha$ -ethoxy-N-[(1S)-2-hydroxy-1-phenylethyl]-4-[2-(2-methyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, ( $\alpha$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220746-62-3 CAPLUS

CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(2-methyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 220746-63-4 CAPLUS

CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(2-methyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, ( $\alpha$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 220746-64-5 CAPLUS

CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(2-methyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, ethyl ester, ( $\alpha$ R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220746-65-6 CAPLUS

CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(2-methyl-4-oxo-3(4H)-

09/179,002


quinazolinyl)ethoxy]-, ethyl ester, ( $\alpha$ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220746-66-7 CAPLUS

CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(4-oxo-3(4H)-quinazolinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 220746-67-8 CAPLUS

CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(4-oxo-3(4H)-quinazolinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 220746-68-9 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]- $\alpha$ -phenoxy-, ethyl ester (9CI) (CA INDEX NAME)



RN 220746-70-3 CAPLUS


09/179,002

CN Benzenepropanoic acid, 4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-  
α-phenoxy- (9CI) (CA INDEX NAME)




RN 220746-71-4 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2-methyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-  
α-phenoxy-, ethyl ester (9CI) (CA INDEX NAME)




RN 220746-72-5 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2-methyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-  
α-phenoxy- (9CI) (CA INDEX NAME)



RN 220746-75-8 CAPLUS


CN Benzenepropanoic acid, 4-[ (3,4-dihydro-4-oxo-3-phenyl-2-  
quinazolinyl)methoxy]-α-ethoxy-, ethyl ester (9CI) (CA INDEX NAME)



RN 220746-76-9 CAPLUS


09/179,002

CN Benzenepropanoic acid, 4-[(3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl)methoxy]- $\alpha$ -ethoxy- (9CI) (CA INDEX NAME)




RN 220746-77-0 CAPLUS

CN Benzenepropanoic acid, 4-[(3,4-dihydro-6,7-dimethoxy-3-methyl-4-oxo-2-quinazolinyl)methoxy]- $\alpha$ -ethoxy-, ethyl ester (9CI) (CA INDEX NAME)




RN 220746-78-1 CAPLUS

CN Benzenepropanoic acid, 4-[(3,4-dihydro-6,7-dimethoxy-3-methyl-4-oxo-2-quinazolinyl)methoxy]- $\alpha$ -ethoxy- (9CI) (CA INDEX NAME)




RN 220746-79-2 CAPLUS

CN Benzenepropanoic acid, 4-[[3,4-dihydro-3-(4-methylphenyl)-4-oxo-2-quinazolinyl)methoxy]- $\alpha$ -ethoxy-, ethyl ester (9CI) (CA INDEX NAME)




RN 220746-80-5 CAPLUS

CN Benzenepropanoic acid, 4-[3,4-dihydro-3-(4-methylphenyl)-4-oxo-2-quinazolinyl]methoxy-α-ethoxy- (9CI) (CA INDEX NAME)




RN 220746-81-6 CAPLUS

CN Benzenepropanoic acid, 4-[3,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-quinazolinyl]methoxy-α-ethoxy-, ethyl ester (9CI) (CA INDEX NAME)



RN 220746-82-7 CAPLUS


CN Benzenepropanoic acid, 4-[3,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-quinazolinyl]methoxy-α-ethoxy- (9CI) (CA INDEX NAME)



RN 220746-83-8 CAPLUS


09/179,002

CN Benzenepropanoic acid, 4-[[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]methoxy]- $\alpha$ -ethoxy-, ethyl ester (9CI) (CA INDEX NAME)





RN 220746-85-0 CAPLUS

CN Benzenepropanoic acid, 4-[[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]methoxy]- $\alpha$ -ethoxy- (9CI) (CA INDEX NAME)



RN 220746-86-1 CAPLUS



CN Benzenepropanoic acid, 4-[[3-(3-chlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]methoxy]- $\alpha$ -ethoxy-, ethyl ester (9CI) (CA INDEX NAME)



RN 220746-87-2 CAPLUS


CN Benzenepropanoic acid, 4-[[3-(3-chlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]methoxy]- $\alpha$ -ethoxy- (9CI) (CA INDEX NAME)

09/179,002




RN 220746-88-3 CAPLUS

CN Benzenepropanoic acid, 4-[[3-(3-chloro-4-fluorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]methoxy]- $\alpha$ -ethoxy-, ethyl ester (9CI) (CA INDEX NAME)



RN 220746-89-4 CAPLUS

CN Benzenepropanoic acid, 4-[[3-(3-chloro-4-fluorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]methoxy]- $\alpha$ -ethoxy- (9CI) (CA INDEX NAME)



=> log y  
COST IN U.S. DOLLARS  
FULL ESTIMATED COST

SINCE FILE ENTRY	TOTAL SESSION
10.99	178.14

STN INTERNATIONAL LOGOFF AT 15:55:04 ON 14 MAY 2006